PPARA and congestive heart failure: However, clinical use of PPAR ligands as thiazolidinediones or glitazars has been restricted by their side effect profile, namely, fluid retention, congestive heart failure (CHF), adipogenic weight gain, kidney impairment and a decrease in bone mineral density associated with fractures.7–11